Drugs / CDX-7108
Trials 0
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Comparator or background therapy1 trial | ||||||
| Phase 1 | NCT05082051 Comparator | Oct 2021 → Mar 2023 | exocrine pancreatic insufficiency | Nestlé | Completed | No outcome recorded |
Press releases naming this drug 3 releases
| Date | Issuer | Release |
|---|---|---|
| 2023-12-27 | Codexis Inc. | Codexis Announces Purchase Agreement with Nestlé Health Science for CDX-7108 codexis.com ↗ |
| 2023-02-23 | Codexis Inc. | Codexis and Nestlé Health Science Announce Interim Results from Phase 1 Clinical Trial of CDX-7108 for Exocrine Pancreatic Insufficiency codexis.com ↗ |
| 2021-11-03 | Codexis Inc. | Codexis and Nestlé Health Science Initiate a Phase 1 Clinical Trial of CDX-7108 for Exocrine Pancreatic Insufficiency codexis.com ↗ |
Evidence & citations 3 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | CDX-7108 | “CDX-7108, an oral recombinant lipase.” NCT05082051 ↗ |
| Modality | Protein / enzyme biologic | “an oral recombinant lipase” NCT05082051 ↗ |
| Route | Oral | “single oral dose administration” NCT05082051 ↗ |